References
- Bandelow, B, Zohar, J, Hollander, E, Kasper, S, Möller, HJ, on behalf of the WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. 2008. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – first revision. World J Biol Psychiatry, 9:248–312.
- Bharucha KJ, Sethi KD. Complex movement disorders induced by fluoxetine. Mov Disord 1996; 11: 324–326
- Bilen S, Saka M, Ak F, Oztekin N. Persistent dystonia induced by fluoxetine. Intern Med J 2008; 38: 672–674
- Dubovsky SL, Thomas M. Tardive dyskinesia associated with fluoxetine. Psychiatr Serv 1996; 47: 991–993
- Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998; 32: 692–698
- Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449–54
- Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003; 17: 47–62
- Naidu PS, Singh A, Kaur P, Sandhir R, Kulkarni SK. Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia. Pharmacol Biochem Behav 2003; 74: 641–648
- Reiter RJ, Tan DX, Mayo JC, Sainz RM, Leon J, Czarnocki Z. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003; 50: 1129–1146
- Shamir E, Barak Y, Shalman I. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001; 58: 1049–1052